Vigil + Irinotecan and Temozolomide in Ewing's Sarcoma
Status:
Active, not recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, 1:1 randomized Phase III study of intradermal autologous Vigil
immunotherapy (1.0 x 10e6 cells/injection; minimum of 4 to a maximum of 12 administrations)
in combination with irinotecan and temozolomide in subjects with metastatic Ewing's sarcoma
Family of Tumors (ESFT) refractory/intolerant or recurrent to 1 prior line of chemotherapy.
Participants undergoing a standard surgical procedure (e.g., tumor biopsy or palliative
resection) may have tumor tissue harvested for manufacture of the investigational product,
Vigil.